Bajaj Healthcare Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹176 Cr +18.9% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
BH

Bajaj Healthcare Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Bajaj Healthcare Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹166Cr
+11.4% YoY
+8.5% QoQ
Net profit
₹14Cr
+16.7% YoY
Turned profitable QoQ
Margin
17%
+1 pp YoY
+2 pp QoQ
Price₹353
Market cap₹1.1K Cr
P/E19.8

The short version

Bajaj Healthcare expects top-line revenue growth of 10% to 15% for FY27, with similar growth anticipated in FY28. Revenue growth guidance for FY27 and FY28: 10% to 15% annually.

From Bajaj Healthcare Ltd's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

  • Bajaj Healthcare expects top-line revenue growth of 10% to 15% for FY27, with similar growth anticipated in FY28.
  • Peptide manufacturing plant (250 kg capacity) commissioning is targeted for Q4 FY27 with commercial revenue starting in 2028; expected peak revenue from this plant is INR 200-300 crores with EBITDA margins of 18%-20%.
  • Oncology API facility is planned for commercialization by Q4 FY28.
  • Expects near-term revenue from novel drugs such as Cenobamate (~INR 10-12 crores in FY27) and Suvorexant (commercialization by Q4 FY28).
  • Longer-term top-line target is around INR 900-1000 crores within 2-3 years.

2 more points from Bajaj Healthcare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Bajaj Healthcare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Ongoing and planned capital expenditure of INR 40-50 crores annually for the next few years.
  • Commissioning of a dedicated peptide manufacturing facility (capacity ~250 kg per annum) targeted by Q4 FY27.
  • Construction of a dedicated oncology API manufacturing facility planned for commissioning by Q4 FY28.
  • Expansion of DSIR-approved R&D centre at Savli into a large 10,000 sq ft facility expected operational by August 2026.
  • Acquisition of GenRx Pharmaceutical manufacturing facility in Nashik, under NCLT approval, to strengthen formulation and oncology business.

2 more points from Bajaj Healthcare Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Bajaj Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Some relevant insights related to business progress and commercialization timelines include: - Peptide manufacturing plant (250 kg capacity) expected to commercialize in Q4 FY27, with revenues starting from FY28. - Oncology API facility targeted for commissioning by Q4 FY28. - Cenobamate tablet has received SEC recommendation; commercialization tied to regulatory approvals. - Several CDMO partnerships underway, including with eight Indian companies for Cenobamate.

2 more points from Bajaj Healthcare Ltd's call on order book

Create a free account to keep reading this call

Bajaj Healthcare Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Bajaj Healthcare Ltd Q1 FY27 results — key figures

Bajaj Healthcare Ltd Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue166149+11.4%153+8.5%
Operating profit (EBITDA)2925+16%23+26.1%
Operating margin17%16%+1 pp15%+2 pp
Profit before tax1614+14.3%-24—
Net profit (PAT)1412+16.7%-23—
EPS (₹)4.073.75+8.5%-6.79—

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹176 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Bajaj Healthcare's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjivani Paranteral (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Bajaj Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Bajaj Healthcare Ltd Q1 FY27 results?

Bajaj Healthcare expects top-line revenue growth of 10% to 15% for FY27, with similar growth anticipated in FY28. Revenue growth guidance for FY27 and FY28: 10% to 15% annually.

What is Bajaj Healthcare Ltd share price analysis?

Bajaj Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 19.8 with a market cap of ₹1,113 Cr. Investors should review the full earnings analysis for detailed insights.

Is Bajaj Healthcare Ltd planning capital expenditure?

Ongoing and planned capital expenditure of INR 40-50 crores annually for the next few years.

Keep Bajaj Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.